SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Van der Velden A. W.)
 

Search: WFRF:(Van der Velden A. W.) > Melphalan, predniso...

  • Zweegman, Sonja (author)

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • American Society of Hematology,2016

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:1686aaa9-7dd3-458b-9214-7ca95c1b0f0e
  • https://lup.lub.lu.se/record/8573967URI
  • https://doi.org/10.1182/blood-2015-11-679415DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:133289284URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • The combination of melphalan, prednisone and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma (NDMM) who are ineligible for stem-cell transplantation. Long term treatment with thalidomide is hampered by neurotoxicity. Melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy showed promising results, without severe neuropathy emerging. We randomly assigned 668 NDMM patients, ineligible for stem-cell transplantation, between nine 4-weekly cycles of MPT followed by thalidomide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen with thalidomide being replaced by lenalidomide (MPR-R). This multicenter, open-label, randomised phase 3 trial was undertaken by HOVON and the NMSG. The primary endpoint was progression-free survival (PFS). The accrual for the study was completed in October 19, 2012. 318 patients were randomly assigned to receive MPT-T and 319 MPR-R. After a median follow up of 36 months PFS with MPT-T was 20 months (95% CI 18-23 months) versus 23 months (95% CI 19-27 months) with MPR-R (HR 0.87 [0.72-1.04], p=0.12). Response rates were similar, with ≥VGPR 47% and 45% respectively. Hematological toxicity was more pronounced with MPR-R, especially grade 3 and 4 neutropenia: 64 versus 27%. Neuropathy ≥ grade 3 was significantly higher in the MPT-T arm; 16% versus 2% in MPR-R, resulting in a significant shorter duration of maintenance therapy (5 versus 17 months in MPR-R), irrespective of age. MPR-R has no advantage over MPT-T concerning efficacy. The toxicity profile differed with clinically significant neuropathy during thalidomide maintenance versus myelosuppression with MPR.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • van der Holt, Bronno (author)
  • Mellqvist, Ulf-Henrik (author)
  • Salomo, Morten (author)
  • Bos, Gerard M J (author)
  • Levin, Mark-David (author)
  • Visser-Wisselaar, Heleen (author)
  • Hansson, MarkusLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)hema-mha (author)
  • van der Velden, Annette W G (author)
  • Deenik, Wendy (author)
  • Gruber, Astrid (author)
  • Coenen, Juleon L L M (author)
  • Plesner, Torben (author)
  • Klein, Saskia K (author)
  • Tanis, Bea C (author)
  • Szatkowski, Damian L (author)
  • Brouwer, Rolf E (author)
  • Westerman, Matthijs (author)
  • Leys, M Rineke B L (author)
  • Sinnige, Harm A M (author)
  • Haukås, Einar (author)
  • van der Hem, Klaas G (author)
  • Durian, Marc F (author)
  • Mattijssen, E Vera J M (author)
  • van de Donk, Niels W C J (author)
  • Stevens-Kroef, Marian J P L (author)
  • Sonneveld, Pieter (author)
  • Waage, Anders (author)
  • Avdelningen för hematologi och transfusionsmedicinInstitutionen för laboratoriemedicin (creator_code:org_t)

Related titles

  • In:Blood: American Society of Hematology127:9, s. 1109-11161528-00200006-4971

Internet link

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view